A critical evaluation of Anti-IL-13 and Anti-IL-4 strategies in severe asthma

International Archives of Allergy and Immunology

Volumn 170, Issue 2, 2016, Pages 122-131

  Bagnasco, Diego ^a   Ferrando, Matteo ^a   Varricchi, Gilda ^b   Passalacqua, Giovanni ^a   Canonica, Giorgio Walter ^a  

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Biomarkers; Interleukins; Monoclonal antibodies; Personalized medicine; Severe asthma; T helper 2 endotype

Indexed keywords

ANRUKINZUMAB; BIOLOGICAL MARKER; DUPILUMAB; INTERLEUKIN 13; INTERLEUKIN 4; LEBRIKIZUMAB; PASCOLIZUMAB; PITRAKINRA; TRALOKINUMAB; ANTIASTHMATIC AGENT; INTERLEUKIN 13 RECEPTOR; INTERLEUKIN 4 RECEPTOR; MONOCLONAL ANTIBODY;

ASTHMA; DISEASE EXACERBATION; DISEASE SEVERITY; HUMAN; INFLAMMATION; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; TH2 CELL; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; IMMUNOLOGY; METABOLISM; PERSONALIZED MEDICINE; SEVERITY OF ILLNESS INDEX; T LYMPHOCYTE SUBPOPULATION;

ANTI-ASTHMATIC AGENTS; ANTIBODIES, MONOCLONAL; ASTHMA; BIOMARKERS; HUMANS; INTERLEUKIN-13; INTERLEUKIN-4; PRECISION MEDICINE; RECEPTORS, INTERLEUKIN-13; RECEPTORS, INTERLEUKIN-4; SEVERITY OF ILLNESS INDEX; SIGNAL TRANSDUCTION; T-LYMPHOCYTE SUBSETS; TH2 CELLS;

EID: 84982949062     PISSN: 10182438     EISSN: 14230097     Source Type: Journal    
DOI: 10.1159/000447692     Document Type: Review

References (90)

1. Centers for Disease Control and Prevention: Vital signs: asthma prevalence, disease characteristics, and self-management education: United States, 2001-2009 MMWR Morb Mortal Wkly Rep 2011 60 547-552.
2. Vianello A, Caminati M, Crivellaro M, El Mazloum R, Snenghi R, Rossi A, Festi G, Bovo C, Passalacqua G, Canonica GW, Senna G. Fatal asthma. Still an epidemic. Respir Med 2016, in press
3. Accordini S, Corsico AG, Braggion M, Gerbase MW, Gislason D, Gulsvik A, Heinrich J, Janson C, Jarvis D, Jogi R, Pin I, Schoefer Y, Bugiani M, Cazzoletti L, Cerveri I, Marcon A, de Marco R. The cost of persistent asthma in Europe: an international population-based study in adults. Int Arch Allergy Immunol 2013; 160: 93-101.
4. Bateman ED, Boushey HA, Bousquet J, Busse WW, Clark TJ, Pauwels RA, Pedersen SE; GOAL Investigators Group: Can guidelinedefined asthma control be achieved?. The Gaining Optimal Asthma Control study. Am J Respir Crit Care Med 2004; 170: 836-844.
5. Haldar P, Brightling CE, Hargadon B, Gupta S, Monteiro W, Sousa A, Marshall RP, Bradding P, Green RH, Wardlaw AJ, Pavord ID. Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med 2009; 360: 973-984.
6. Corren J, Lemanske RF, Hanania NA, Korenblat PE, Parsey MV, Arron JR, Harris JM, Scheerens H, Wu LC, Su Z, Mosesova S, Eisner MD, Bohen SP, Matthews JG. Lebrikizumab treatment in adults with asthma. N Engl J Med 2011; 365: 1088-1098.
7. Chung KF. Targeting the interleukin pathway in the treatment of asthma. Lancet 2015; 386: 1086-1096.
8. Gadani SP, Cronk JC, Norris GT, Kipnis J. Interleukin-4: a cytokine to remember. J Immunol 2012; 189: 4213-4219.
9. Derecki NC, Cardani AN, Yang CH, Quinnies KM, Crihfield A, Lynch KR, Kipnis J. Regulation of learning and memory by meningeal immunity: a key role for IL-4. J Exp Med 2010; 207: 1067-1080.
10. Lynch MA. Age-related neuroinflammatory changes negatively impact on neuronal function. Front Aging Neurosci 2010; 1: 6.
11. McCormick SM, Heller NM. Commentary: IL-4 and IL-13 receptors and signaling. Cytokine 2015; 75: 38-50.
12. Doucet C, Brouty-Boye D, Pottin-Clemenceau C, Jasmin C, Canonica GW, Azzarone B. IL-4 and IL-13 specifically increase adhesion molecule and inflammatory cytokine expression in human lung fibroblasts. B Int Immunol 1998; 10: 1421-1433.
13. Doucet C, Brouty-Boye D, Pottin-Clemenceau C, Canonica GW, Jasmin C, Azzarone B. Interleukin (IL) 4 and IL-13 act on human lung fibroblasts. Implication in asthma. J Clin Invest 1998; 101: 2129-2139.
14. Richter A, Puddicombe SM, Lordan JL, Bucchieri F, Wilson SJ, Djukanovic R, Dent G, Holgate ST, Davies DE. The contribution of interleukin (IL)-4 and IL-13 to the epithelialmesenchymal trophic unit in asthma. Am J Respir Cell Mol Biol 2001; 25: 385-391.
15. Bosse Y, Thompson C, Audette K, Stankova J, Rola-Pleszczynski M. Interleukin-4 and interleukin-13 enhance human bronchial smooth muscle cell proliferation. Int Arch Allergy Immunol 2008; 146: 138-148.
16. Kondo M, Tamaoki J, Takeyama K, Isono K, Kawatani K, Izumo T, Nagai A. Elimination of IL-13 reverses established goblet cell metaplasia into ciliated epithelia in airway epithelial cell culture. Allergol Int 2006; 55: 329-336.
17. Chiba Y, Nakazawa S, Todoroki M, Shinozaki K, Sakai H, Misawa M. Interleukin-13 augments bronchial smooth muscle contractility with an up-regulation of RhoA protein. Am J Respir Cell Mol Biol 2009; 40: 159-167.
18. Punnonen J, Aversa G, Cocks BG, McKenzie AN, Menon S, Zurawski G, de Waal Malefyt R, de Vries JE. Interleukin 13 induces interleukin 4-independent IgG4 and IgE synthesis and CD23 expression by human B cells. Proc Natl Acad Sci USA 1993; 90: 3730-3734.
19. Horie S, Okubo Y, Hossain M, Sato E, Nomura H, Koyama S, Suzuki J, Isobe M, Sekiguchi M. Interleukin-13 but not interleukin-4 prolongs eosinophil survival and induces eosinophil chemotaxis. Intern Med 1997; 36: 179-185.
20. Luttmann W, Knoechel B, Foerster M, Matthys H, Virchow JC Jr, Kroegel C. Activation of human eosinophils by IL-13. Induction of CD69 surface antigen, its relationship to messenger RNA expression, and promotion of cellular viability. J Immunol 1996; 157: 1678-1683.
21. Davies DE, Wicks J, Powell RM, Puddicombe SM, Holgate ST. Airway remodeling in asthma: new insights. J Allergy Clin Immunol 2003; 111: 215-225; quiz 226.
22. Holgate ST. Innate and adaptive immune responses in asthma. Nat Med 2012; 18: 673-683.
23. KleinJan A. Airway inflammation in asthma: key players beyond the Th2 pathway. Curr Opin Pulm Med 2016; 22: 46-52.
24. Jia G, Erickson RW, Choy DF, Mosesova S, Wu LC, Solberg OD, Shikotra A, Carter R, Audusseau S, Hamid Q, Bradding P, Fahy JV, Woodruff PG, Harris JM, Arron JR; Periostin is a systemic biomarker of eosinophilic airway inflammation in asthmatic patients. Bronchoscopic Exploratory Research Study of Biomarkers in Corticosteroid-refractory Asthma (BOBCAT) Study Group. J Allergy Clin Immunol 2012; 130: 647-654.
25. Nelms K, Keegan AD, Zamorano J, Ryan JJ, Paul WE. The IL-4 receptor: signaling mechanisms and biologic functions. Annu Rev Immunol 1999; 17: 701-738.
26. Oh CK, Geba GP, Molfino N. Investigational therapeutics targeting the IL-4/IL-13/STAT-6 pathway for the treatment of asthma. Eur Respir Rev 2010; 19: 46-54.
27. Gour N, Wills-Karp M. IL-4 and IL-13 signaling in allergic airway disease. Cytokine 2015; 75: 68-78.
28. Corren J. Role of interleukin-13 in asthma. Curr Allergy Asthma Rep. 2013; 13: 415-420.
29. Chiba Y, Goto K, Misawa M. Interleukin-13-induced activation of signal transducer and activator of transcription 6 is mediated by an activation of Janus kinase 1 in cultured human bronchial smooth muscle cells. Pharmacol Rep 2012; 64: 454-458.
30. Sun XJ, Wang L-M, Zhang Y, Yenush L, Myers MG Jr, Glasheen E, Lane WS, Pierce JH, White MF. Role of IRS-2 in insulin and cytokine signalling. Nature 1995; 377: 173-177.
31. Dhand R, Hiles I, Panayotou G, Roche S, Fry MJ, Gout I, Totty NF, Truong O, Vicendo P, Yonezawa K, et al. PI 3-kinase is a dual specificity enzyme: autoregulation by an intrinsic protein-serine kinase activity. EMBO J 1994; 13: 522-533.
32. Ruckerl D, Jenkins SJ, Laqtom NN, Gallagher IJ, Sutherland TE, Duncan S, Buck AH, Allen JE. Induction of IL-4Ralpha-dependent microRNAs identifies PI3K/Akt signaling as essential for IL-4-driven murine macrophage proliferation in vivo. Blood 2012; 120: 2307-2316.
33. Heller NM, Qi X, Gesbert F, Keegan AD. The extracellular and transmembrane domains of the gammaC and interleukin (IL)-13 receptor alpha1 chains, not their cytoplasmic domains, dictate the nature of signaling responses to IL-4 and IL-13. J Biol Chem 2012; 287: 31948-31961.
34. Karlsson HR, Zierath J. Insulin signaling and glucose transport in insulin resistant human skeletal muscle. Cell Biochem Biophys 2007; 48: 103-113.
35. Landis J, Shaw LM. Insulin receptor substrate-2 mediated phosphatidylinositol-3-kinase signaling selectively inhibits glycogen synthase kinase-3b to regulate aerobic glycolysis. J Biol Chem 2014; 289: 18603-18613.
36. Russo SJ, Bolanos CA, Theobald DE, DeCarolis NA, Renthal W, Kumar A, Winstanley CA, Renthal NE, Wiley MD, Self DW, Russell DS, Neve RL, Eisch AJ, Nestler EJ. IRS2-Akt pathway in midbrain dopamine neurons regulates behavioral and cellular responses to opiates. Nat Neurosci 2007; 10: 93-99.
37. Mikita T, Campbell D, Wu P, Williamson K, Schindler U. Requirements for interleukin-4-induced gene expression and functional characterization of Stat6. Mol Cell Biol 1996; 16: 5811-5820.
38. Shen C-H, Stavnezer J. Interaction of stat6 and NF-?B: direct association and synergistic activation of interleukin-4-induced transcription. Mol Cell Biol 1998; 18: 3395-3404.
39. Delphin S, Stavnezer J. Characterization of an interleukin 4 (IL-4) responsive region in the immunoglobulin heavy chain germline epsilon promoter: regulation by NF-IL-4, a C/ EBP family member and NF-?B/p50. J Exp Med 1995; 181: 181-192.
40. Zheng T, Liu W, Oh SY, Zhu Z, Hu B, Homer RJ, Cohn L, Grusby MJ, Elias JA. IL-13 receptor alpha2 selectively inhibits IL-13-induced responses in the murine lung. J Immunol 2008; 180: 522-529.
41. Xie M, Wu XJ, Zhang JJ, He CS: IL-13 receptor a2 is a negative prognostic factor in human lung cancer and stimulates lung cancer growth in mice Oncotarget 2015 6 32902-32913.
42. Bartminski G, Crossley M, Turcanu V. Novel biomarkers for asthma stratification and personalized therapy. Expert Rev Mol Diagn 2015; 15: 415-430.
43. Munoz X, Bustamante V, Lopez-Campos JL, Cruz MJ, Barreiro E. Usefulness of noninvasive methods for the study of bronchial inflammation in the control of patients with asthma. Int Arch Allergy Immunol 2015; 166: 1-12.
44. Woodruff PG, Modrek B, Choy DF, Jia G, Abbas AR, Ellwanger A, Koth LL, Arron JR, Fahy JV. T-helper type 2-driven inflammation defines major subphenotypes of asthma. Am J Respir Crit Care Med 2009; 180: 388-395.
45. Wenzel SE, Schwartz LB, Langmack EL, Halliday JL, Trudeau JB, Gibbs RL, Chu HW. Evidence that severe asthma can be divided pathologically into two inflammatory subtypes with distinct physiologic and clinical characteristics. Am J Respir Crit Care Med 1999; 160: 1001-1008.
46. Spanevello A, Confalonieri M, Sulotto F, Romano F, Balzano G, Migliori GB, Bianchi A, Michetti G. Induced sputum cellularity. Reference values and distribution in normal volunteers. Am J Respir Crit Care Med 2000; 162: 1172-1174.
47. Dente FL, Latorre M, Novelli F, Cianchetti S, Bartoli ML, Bacci E, Di Franco A, Vagaggini B, Celi A, Paggiaro P. Can Sputum eosinophilia be a constant feature in severe refractory asthmatics?. A 3-year longitudinal study. Int Arch Allergy Immunol 2015; 166: 287-290.
48. Saha SK, Berry MA, Parker D, Siddiqui S, Morgan A, May R, Monk P, Bradding P, Wardlaw AJ, Pavord ID, Brightling CE. Increased sputum and bronchial biopsy IL-13 expression in severe asthma. J Allergy Clin Immunol 2008; 121: 685-691.
49. Kuiper S, Muris JW, Dompeling E, van Schayck CP, Schonberger HJ, Wesseling G, Knottnerus JA. Association between first-degree familial predisposition of asthma and atopy (total IgE) in newborns. Clin Exp Allergy 2006; 36: 594-601.
50. Chibana K, Trudeau JB, Mustovich AT, Hu H, Zhao J, Balzar S, Chu HW, Wenzel SE. IL-13 induced increases in nitrite levels are primarily driven by increases in inducible nitric oxide synthase as compared with effects on arginases in human primary bronchial epithelial cells. Clin Exp Allergy 2008; 8: 936-946.
51. Smith AD, Cowan JO, Brassett KP, Filsell S, McLachlan C, Monti-Sheehan G, Peter Herbison G, Robin Taylor D. Exhaled nitric oxide: a predictor of steroid response. Am J Respir Crit Care Med 2005; 172: 453-459.
52. Brown HM. Treatment of chronic asthma with prednisolone; significance of eosinophils in the sputum. Lancet 1958; 2: 1245-1247.
53. Pavord ID, Brightling CE, Woltmann G, Wardlaw AJ. Non-eosinophilic corticosteroid unresponsive asthma. Lancet 1999; 353: 2213-2214.
54. Gillan L, Matei D, Fishman DA, Gerbin CS, Karlan BY, Chang DD. Periostin secreted by epithelial ovarian carcinoma is a ligand for alpha(V)beta(3) and alpha(V)beta(5) integrins and promotes cell motility. Cancer Res 2002; 62: 5358-5364.
55. Wang X, Liu J, Wang Z, Huang Y, Liu W, Zhu X, Cai Y, Fang X, Lin S, Yuan L, Ouyang G. Periostin contributes to the acquisition of multipotent stem cell-like properties in human mammary epithelial cells and breast cancer cells. PLoS One 2013; 8: e72962.
56. Sidhu SS, Yuan S, Innes AL, Kerr S, Woodruff PG, Hou L, Muller SJ, Fahy JV. Roles of epithelial cell-derived periostin in TGF-beta activation, collagen production, and collagen gel elasticity in asthma. Proc Natl Acad Sci USA 2010; 107: 14170-14175.
57. Xanthou G, Alissafi T, Semitekolou M, Simoes DC, Economidou E, Gaga M, Lambrecht BN, Lloyd CM, Panoutsakopoulou V. Osteopontin has a crucial role in allergic airway disease through regulation of dendritic cell subsets. Nat Med 2007; 13: 570-578.
58. Takayama G, Arima K, Kanaji T, Toda S, Tanaka H, Shoji S, McKenzie AN, Nagai H, Hotokebuchi T, Izuhara K. Periostin: a novel component of subepithelial fibrosis of bronchial asthma downstream of IL-4 and IL-13 signals. J Allergy Clin Immunol 2006; 118: 98-104.
59. Kanemitsu Y, Matsumoto H, Izuhara K, Tohda Y, Kita H, Horiguchi T, Kuwabara K, Tomii K, Otsuka K, Fujimura M, Ohkura N, Tomita K, Yokoyama A, Ohnishi H, Nakano Y, Oguma T, Hozawa S, Nagasaki T, Ito I, Oguma T, Inoue H, Tajiri T, Iwata T, Izuhara Y, Ono J, Ohta S, Tamari M, Hirota T, Yokoyama T, Niimi A, Mishima M. Increased periostin associates with greater airflow limitation in patients receiving inhaled corticosteroids. J Allergy Clin Immunol 2013; 132: 305-312.
60. Delimpoura V, Bakakos P, Tseliou E, Bessa V, Hillas G, Simoes DC, Papiris S, Loukides S. Increased levels of osteopontin in sputum supernatant in severe refractory asthma. Thorax 2010; 65: 782-786.
61. Nagasaki T, Matsumoto H, Kanemitsu Y, Izuhara K, Tohda Y, Kita H, Horiguchi T, Kuwabara K, Tomii K, Otsuka K, Fujimura M, Ohkura N, Tomita K, Yokoyama A, Ohnishi H, Nakano Y, Oguma T, Hozawa S, Ito I, Oguma T, Inoue H, Tajiri T, Iwata T, Izuhara Y, Ono J, Ohta S, Yokoyama T, Niimi A, Mishima M. Integrating longitudinal information on pulmonary function and inflammation using asthma phenotypes. J Allergy Clin Immunol 2014; 133: 1474-1477.
62. Nagasaki T, Matsumoto H, Kanemitsu Y, Izuhara K, Tohda Y, Horiguchi T, Kita H, Tomii K, Fujimura M, Yokoyama A, Nakano Y, Hozawa S, Ito I, Oguma T, Izuhara Y, Tajiri T, Iwata T, Ono J, Ohta S, Yokoyama T, Niimi A, Mishima M. Using exhaled nitric oxide and serum periostin as a composite marker to identify severe/steroid-insensitive asthma. Am J Respir Crit Care Med 2014; 190: 1449-1452.
63. De Ferrari L, Chiappori A, Bagnasco D, Riccio AM, Passalacqua G, Canonica GW. Molecular phenotyping and biomarker development: are we on our way towards targeted therapy for severe asthma?. Expert Rev Respir Med 2016; 10: 29-38.
64. Hua F, Ribbing J, Reinisch W, Cataldi F, Martin S. A pharmacokinetic comparison of anrukinzumab, an anti-IL-13 monoclonal antibody, among healthy volunteers, asthma and ulcerative colitis patients. Br J Clin Pharmacol 2015; 80: 101-109.
65. Ultsch M, Bevers J, Nakamura G, Vandlen R, Kelley RF, Wu LC, Eigenbrot C. Structural basis of signaling blockade by anti-IL-13 antibody lebrikizumab. J Mol Biol 2013; 425: 1330-1339.
66. Scheerens H, Arron JR, Zheng Y, Putnam WS, Erickson RW, Choy DF, Harris JM, Lee J, Jarjour NN, Matthews JG. The effects of lebrikizumab in patients with mild asthma following whole lung allergen challenge. Clin Exp Allergy 2014; 44: 38-46.
67. Hanania NA, Noonan M, Corren J, Korenblat P, Zheng Y, Fischer SK, Cheu M, Putnam WS, Murray E, Scheerens H, Holweg CT, Maciuca R, Gray S, Doyle R, McClintock D, Olsson J, Matthews JG, Yen K. Lebrikizumab in moderate-To-severe asthma: pooled data from two randomised placebo-controlled studies. Thorax 2015; 70: 748-756.
68. Noonan M, Korenblat P, Mosesova S, Scheerens H, Arron JR, Zheng Y, Putnam WS, Parsey MV, Bohen SP, Matthews JG. Doseranging study of lebrikizumab in asthmatic patients not receiving inhaled steroids. J Allergy Clin Immunol 2013; 132: 567-574.e12.
69. Piper E, Brightling C, Niven R, Oh C, Faggioni R, Poon K, She D, Kell C, May RD, Geba GP, Molfino NA. A phase II placebocontrolled study of tralokinumab in moderate-To-severe asthma. Eur Respir J 2013; 41: 330-338.
70. Brightling CE, Chanez P, Leigh R, O?Byrne PM, Korn S, She D, May RD, Streicher K, Ranade K, Piper E. Efficacy and safety of tralokinumab in patients with severe uncontrolled asthma: a randomised, double-blind, placebo-controlled, phase 2b trial. Lancet Respir Med 2015; 3: 692-701.
71. Murray LA, Zhang H, Oak SR, Coelho AL, Herath A, Flaherty KR, Lee J, Bell M, Knight DA, Martinez FJ, Sleeman MA, Herzog EL, Hogaboam CM. Targeting interleukin-13 with tralokinumab attenuates lung fibrosis and epithelial damage in a humanized SCID idiopathic pulmonary fibrosis model. Am J Respir Cell Mol Biol 2014; 50: 985-994.
72. Ricci M. IL-4: a key cytokine in atopy. Clin Exp Allergy 1994; 24: 801-812.
73. Pauwels RA, Brusselle GG, Tournoy KG, Lambrecht BN, Kips JC. Cytokines and their receptors as therapeutic targets in asthma. Clin Exp Allergy 1998; 28(suppl 3): 1-5.
74. Ricci M, Matucci A, Rossi O. IL-4 as a key factor influencing the development of allergenspecific Th2-like cells in atopic individuals. J Invest Allergol Clin Immunol 1997; 7: 144-150.
75. Garlisi CG, Kung TT, Wang P Minnicozzi M, Umland SP, Chapman RW, Stelts D, Crawley Y, Falcone A, Myers JG, Jones H, Billah MM, Kreutner W, Egan RW. Effects of chronic anti-interleukin-5 monoclonal antibody treatment in a murine model of pulmonary inflammation. Am J Respir Cell Mol Biol 1999; 20: 248-255.
76. Buttner C, Skupin A, Reimann T, Rieber EP, Unteregger G, Geyer P, Frank KH. Local production of interleukin-4 during radiation-induced pneumonitis and pulmonary fibrosis in rats: macrophages as a prominent source of interleukin-4. Am J Respir Cell Mol Biol 1997; 17: 315-325.
77. Barlow JL, McKenzie AN. Type-2 innate lymphoid cells in human allergic disease. Curr Opin Allergy Clin Immunol 2014; 14: 397-403.
78. Walford HH, Lund SJ, Baum RE, White AA, Bergeron CM, Husseman J, Bethel KJ, Scott DR, Khorram N, Miller M, Broide DH, Doherty TA. Increased ILC2s in the eosinophilic nasal polyp endotype are associated with corticosteroid responsiveness. Clin Immunol 2014; 155: 126e135.
79. Bartemes KR, Kephart GM, Fox SJ, Kita H. Enhanced innate type 2 immune response in peripheral blood from patients with asthma. J Allergy Clin Immunol 2014; 134: 671-678.e4.
80. Liu T, Wu J, Zhao J, Wang J, Zhang Y, Liu L, Cao L, Liu Y, Dong L. Type 2 innate lymphoid cells: A novel biomarker of eosinophilic airway inflammation in patients with mild to moderate asthma. Respir Med 2015; 109: 1391-1396.
81. Hart TK, Blackburn MN, Brigham-Burke M, Dede K, Al-Mahdi N, Zia-Amirhosseini P, Cook RM. Preclinical efficacy and safety of pascolizumab (SB 240683): a humanized antiinterleukin-4 antibody with therapeutic potential in asthma. Clin Exp Immunol 2002; 130: 93-100.
82. Walker BL, Leigh R. Use of biologicals as immunotherapy in asthma and related diseases. Expert Rev Clin Immunol 2008; 4: 743-756.
83. Pelaia G, Vatrella A, Maselli R. The potential of biologics for the treatment of asthma. Nat Rev Drug Discov 2012; 11: 958-972.
84. Slager RE, Otulana BA, Hawkins GA, Yen YP, Peters SP, Wenzel SE, Meyers DA, Bleecker ER. IL-4 receptor polymorphisms predict reduction in asthma exacerbations during response to an anti-IL-4 receptor a antagonist. J Allergy Clin Immunol 2012; 130: 516-522.e4.
85. Wenzel S, Wilbraham D, Fuller R, Getz EB, Longphre M. Effect of an interleukin-4 variant on late phase asthmatic response to allergen challenge in asthmatic patients: results of two phase 2a studies. Lancet 2007; 370: 1422-1431.
86. Wechsler ME. Inhibiting interleukin-4 and interleukin-13 in difficult-To-control asthma. N Engl J Med 2013; 368: 2511-2513.
87. Wenzel S, Ford L, Pearlman D, Spector S, Sher L, Skobieranda F, Wang L, Kirkesseli S, Rocklin R, Bock B, Hamilton J, Ming JE, Radin A, Stahl N, Yancopoulos GD, Graham N, Pirozzi G. Dupilumab in persistent asthma with elevated eosinophil levels. N Engl J Med 2013; 368: 2455-2466.
88. Vatrella A, Fabozzi I, Calabrese C, Maselli R, Pelaia G. Dupilumab: a novel treatment for asthma. J Asthma Allergy 2014; 7: 123-130.
89. Tsianakas A, Stander S. Dupilumab: a milestone in the treatment of atopic dermatitis. Lancet 2016; 387: 4-5.
90. Bachert C, Mannent L, Naclerio RM, Mullol J, Ferguson BJ, Gevaert P, Hellings P, Jiao L, Wang L, Evans RR, Pirozzi G, Graham NM, Swanson B, Hamilton JD, Radin A, Gandhi NA, Stahl N, Yancopoulos GD, Sutherland R. Effect of subcutaneous dupilumab on nasal polyp burden in patients with chronic sinusitis and nasal polyposis. A randomized clinical trial. JAMA 2016; 315: 469-479.